<!DOCTYPE MedlineCitationSet
PUBLIC "-//NLM//DTD MEDLINE, 11th December 2000//EN"
"http://www.nlm.nih.gov/databases/dtd/nlmmedline_001211.dtd">
<MedlineCitationSet>
<MedlineCitation>
<MedlineID>96264942</MedlineID>
<PMID>8655018</PMID>
<DateCreated>
<Year>1996</Year>
<Month>07</Month>
<Day>30</Day>
</DateCreated>
<DateCompleted>
<Year>1996</Year>
<Month>07</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0017-0011</ISSN>
<JournalIssue>
<Volume>67</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1996</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>[Effect of fetal and neonatal growth on the occurrence of some diseases in adults]</ArticleTitle>
<Pagination>
<MedlinePgn>34-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The findings of many authors show that reduced fetal growth is followed by increased mortality from cardiovascular disease in adult life. They are further evidence that cardiovascular disease originates, among other risk factors, through programming of the bodies structure and metabolism during fetal and early post-natal life. Wrong maternal nutrition may have an important influence on programming.</AbstractText>
</Abstract>
<Affiliation>Katedry i Zakładu Chemii i Analizy Leków, AM w Katowicach.</Affiliation>
<AuthorList>
<Author>
<LastName>Jendryczko</LastName>
<FirstName>A</FirstName>
<Initials>A</Initials>
</Author>
<Author>
<LastName>Poreba</LastName>
<FirstName>R</FirstName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>pol</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Retracted Publication</PublicationType>
<PublicationType>Review</PublicationType>
<PublicationType>Review, Tutorial</PublicationType>
</PublicationTypeList>
<VernacularTitle>Wpływ przebiegu rozwoju płodu i noworodka na ujawnienie sie niektórych chorób okresu dorosłego.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>POLAND</Country>
<MedlineTA>Ginekol Pol</MedlineTA>
<MedlineCode>FR3</MedlineCode>
<NlmUniqueID>0374641</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrections>
<CommentIn>
<RefSource>Ginekol Pol. 1998 Jul;69(7):561</RefSource>
</CommentIn>
<RetractionIn>
<RefSource>Ginekol Pol 1998 Jul;69(7):559-60</RefSource>
</RetractionIn>
</CommentsCorrections>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Adult</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Cardiovascular Diseases</Descriptor>
<SubHeading>etiology</SubHeading>
<SubHeading MajorTopicYN="Y">mortality</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Child Development</Descriptor>
<SubHeading MajorTopicYN="Y">physiology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>English Abstract</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Fetal Development</Descriptor>
<SubHeading MajorTopicYN="Y">physiology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Fetal Growth Retardation</Descriptor>
<SubHeading>complications</SubHeading>
<SubHeading MajorTopicYN="Y">physiopathology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Human</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Infant, Newborn</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Nutrition</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Risk Factors</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Survival Rate</Descriptor>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>11</NumberOfReferences>
</MedlineCitation>
<MedlineCitation>
<MedlineID>97017246</MedlineID>
<PMID>8863847</PMID>
<DateCreated>
<Year>1996</Year>
<Month>11</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>1996</Year>
<Month>11</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0026-895X</ISSN>
<JournalIssue>
<Volume>50</Volume>
<Issue>4</Issue>
<PubDate>
<Year>1996</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Mechanism of extracellular ATP-induced proliferation of vascular smooth muscle cells.</ArticleTitle>
<Pagination>
<MedlinePgn>1000-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The mitogenic effect of extracellular ATP was examined in cultured rat aortic smooth muscle cells (VSMCs). ATP, 2-methylthio-ATP, and ADP stimulated [3H]thymidine and [3H]leucine incorporation and cell growth. AMP, adenosine, UTP, and P2x agonists showed little of these effects. Reactive blue 2, a P2Y purinoceptor antagonist, was effective in suppressing the mitogenic effect of ATP and 2-methylthio-ATP, indicating that extracellular ATP-induced VSMC proliferation is mediated by P2Y purinoceptors. The P2Y purinoceptor activation was coupled to a pertussis toxin (PTX)-insensitive G protein (Gq) and triggered phosphoinositide hydrolysis with subsequent activation of protein kinase C (PKC), Raf-1, and mitogen-activated protein kinase (MAPK) in VSMCs. In response to ATP, both 42-and 44-kDa MAPKs were activated, and tyrosine was phosphorylated. Western blot analysis using PKC isozyme-specific antibodies indicated that VSMCs express PKC-alpha, PKC-delta, and PKC-zeta. A complete down-regulation of PKC-alpha and PKC-delta was seen after 24-hr treatment with 12-O-tetradecanoylphorbol-13-acetate. When cells were pretreated with 12-O-tetradecanoyl-phorbol-13-acetate for 24 hr and subsequently challenged with ATP, Raf-1 activation and 42-kDa as well as 44-kDa MAPK tyrosine phosphorylation failed to be induced. These results demonstrate that ATP-induced Raf-1 and MAPK activations involve the activation of PKC-alpha and PKC-delta. P2Y purinoceptor stimulation with ATP also caused accumulation of c-fos and c-myc mRNAs. Both Reactive blue 2 and staurosporine significantly blocked this increase by ATP. In conclusion, the mitogenic effect of ATP seemed to be triggered by activation of the Gq protein-coupled P2Y purinoceptor that led to the formation of inositol trisphosphate and activation of PKC. PKC and, in turn, Raf-1 and MAPK were then activated, leading eventually to DNA synthesis and cell proliferation.</AbstractText>
</Abstract>
<Affiliation>Department of Pharmacology, Chang Gung College of Medicine and Technology, Kwei-San, Tao-Yuan, Taiwan. smyu@cguaplo.cgu.edu</Affiliation>
<AuthorList>
<Author>
<LastName>Yu</LastName>
<FirstName>S</FirstName>
<MiddleName>M</MiddleName>
<Initials>SM</Initials>
</Author>
<Author>
<LastName>Chen</LastName>
<FirstName>S</FirstName>
<MiddleName>F</MiddleName>
<Initials>SF</Initials>
</Author>
<Author>
<LastName>Lau</LastName>
<FirstName>Y</FirstName>
<MiddleName>T</MiddleName>
<Initials>YT</Initials>
</Author>
<Author>
<LastName>Yang</LastName>
<FirstName>C</FirstName>
<MiddleName>M</MiddleName>
<Initials>CM</Initials>
</Author>
<Author>
<LastName>Chen</LastName>
<FirstName>J</FirstName>
<MiddleName>C</MiddleName>
<Initials>JC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Retracted Publication</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Mol Pharmacol</MedlineTA>
<MedlineCode>NGR</MedlineCode>
<NlmUniqueID>0035623</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Proto-Oncogene Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Receptors, Purinergic P2</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>10028-17-8</CASRegistryNumber>
<NameOfSubstance>Tritium</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>50-89-5</CASRegistryNumber>
<NameOfSubstance>Thymidine</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>56-65-5</CASRegistryNumber>
<NameOfSubstance>Adenosine Triphosphate</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>7005-03-0</CASRegistryNumber>
<NameOfSubstance>Leucine</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>9007-49-2</CASRegistryNumber>
<NameOfSubstance>DNA</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>EC 2.7.1.-</CASRegistryNumber>
<NameOfSubstance>Protein Kinase C</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>EC 2.7.10</CASRegistryNumber>
<NameOfSubstance>Protein-Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>EC 2.7.10.-</CASRegistryNumber>
<NameOfSubstance>Ca(2+)-Calmodulin Dependent Protein Kinase</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>EC 2.7.10.-</CASRegistryNumber>
<NameOfSubstance>Proto-Oncogene Proteins c-raf</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>EC 3.6.1.-</CASRegistryNumber>
<NameOfSubstance>GTP-Binding Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrections>
<ErratumIn>
<RefSource>Mol Pharmacol 1997 Mar;51(3):533</RefSource>
</ErratumIn>
<RetractionIn>
<RefSource>Wu D, Yang CM, Lau YT, Chen JC. Mol Pharmacol 1998 Feb;53(2):346</RefSource>
</RetractionIn>
</CommentsCorrections>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Adenosine Triphosphate</Descriptor>
<SubHeading MajorTopicYN="Y">pharmacology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Animal</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Aorta</Descriptor>
<SubHeading>cytology</SubHeading>
<SubHeading>drug effects</SubHeading>
<SubHeading>metabolism</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Ca(2+)-Calmodulin Dependent Protein Kinase</Descriptor>
<SubHeading>metabolism</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Cell Count</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Cell Division</Descriptor>
<SubHeading>drug effects</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Cells, Cultured</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>DNA</Descriptor>
<SubHeading>biosynthesis</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Enzyme Activation</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Extracellular Space</Descriptor>
<SubHeading>metabolism</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>GTP-Binding Proteins</Descriptor>
<SubHeading>metabolism</SubHeading>
<SubHeading>physiology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>In Vitro</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Leucine</Descriptor>
<SubHeading>metabolism</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Muscle, Smooth, Vascular</Descriptor>
<SubHeading MajorTopicYN="Y">cytology</SubHeading>
<SubHeading MajorTopicYN="Y">drug effects</SubHeading>
<SubHeading>metabolism</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Protein Kinase C</Descriptor>
<SubHeading>metabolism</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Protein-Serine-Threonine Kinases</Descriptor>
<SubHeading>metabolism</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Proto-Oncogene Proteins</Descriptor>
<SubHeading>metabolism</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Proto-Oncogene Proteins c-raf</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>RNA, Messenger</Descriptor>
<SubHeading>metabolism</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Rats</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Rats, Sprague-Dawley</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Receptors, Purinergic P2</Descriptor>
<SubHeading>physiology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Signal Transduction</Descriptor>
<SubHeading>physiology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Stimulation, Chemical</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Support, Non-U.S. Gov't</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Thymidine</Descriptor>
<SubHeading>metabolism</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Transcription Factors</Descriptor>
<SubHeading>biosynthesis</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Tritium</Descriptor>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>97096070</MedlineID>
<PMID>8941094</PMID>
<DateCreated>
<Year>1997</Year>
<Month>01</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted>
<Year>1997</Year>
<Month>01</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0009-7322</ISSN>
<JournalIssue>
<Volume>94</Volume>
<Issue>11</Issue>
<PubDate>
<Year>1996</Year>
<Month>Dec</Month>
<Day>1</Day>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-hour-24-hour 201Tl tomography versus dobutamine echocardiography.</ArticleTitle>
<Pagination>
<MedlinePgn>2712-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>BACKGROUND: To date, late redistribution after resting 201Tl injection has not been evaluated. In addition, the concordance between resting 201Tl imaging and dobutamine echocardiography in identifying viable myocardium has not been assessed. METHODS AND RESULTS: Forty patients with coronary artery disease underwent rest-4-hour-24-hour 201Tl tomography and dobutamine echocardiography (5 to 10 micrograms.kg-1.min-1). Late redistribution occurred in 46 (21%) of 219 persistent defects at 4 hours. Systolic function and contractile reserve were similar among persistent defects at 4 hours with and without late redistribution. Contractile reserve was more frequent in segments with normal 201Tl uptake (59%), completely reversible defects (53%), or mild to moderate defects at 4 hours (56%) compared with severe defects (14%; P &#60; .02 versus all). Of 105 hypokinetic segments, 99 (94%) were viable by 201Tl, and 88 (84%) showed contractile reserve. In contrast, of 155 akinetic segments, 119 (77%) were viable by 201Tl, but only 34 (22%) had contractile reserve. Concordance between 201Tl and dobutamine was 82% in hypokinetic segments but 43% in akinetic segments. In 109 revascularized segments, positive accuracy for functional recovery was 72% for 201Tl and 92% for dobutamine, whereas negative accuracy was 100% and 65%, respectively. Sensitivity was 100% for 201Tl and 79% for dobutamine. CONCLUSIONS: Late redistribution occurs in one fifth of persistent defects at 4 hours, and it does not correlate to systolic function or contractile reserve. Dobutamine and 201Tl yield concordant information in the majority of hypokinetic segments, whereas concordance is low in akinetic segments. Dobutamine demonstrates higher positive accuracy and sensitivity in predicting recovery of dysfunctional myocardium, whereas 201Tl shows higher negative predictive accuracy but reduced positive accuracy.</AbstractText>
</Abstract>
<Affiliation>Division of Cardiology, Federico II University Medical School, Naples, Italy.</Affiliation>
<AuthorList>
<Author>
<LastName>Perrone-Filardi</LastName>
<FirstName>P</FirstName>
<Initials>P</Initials>
</Author>
<Author>
<LastName>Pace</LastName>
<FirstName>L</FirstName>
<Initials>L</Initials>
</Author>
<Author>
<LastName>Prastaro</LastName>
<FirstName>M</FirstName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Squame</LastName>
<FirstName>F</FirstName>
<Initials>F</Initials>
</Author>
<Author>
<LastName>Betocchi</LastName>
<FirstName>S</FirstName>
<Initials>S</Initials>
</Author>
<Author>
<LastName>Soricelli</LastName>
<FirstName>A</FirstName>
<Initials>A</Initials>
</Author>
<Author>
<LastName>Piscione</LastName>
<FirstName>F</FirstName>
<Initials>F</Initials>
</Author>
<Author>
<LastName>Indolfi</LastName>
<FirstName>C</FirstName>
<Initials>C</Initials>
</Author>
<Author>
<LastName>Crisci</LastName>
<FirstName>T</FirstName>
<Initials>T</Initials>
</Author>
<Author>
<LastName>Salvatore</LastName>
<FirstName>M</FirstName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Chiariello</LastName>
<FirstName>M</FirstName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Circulation</MedlineTA>
<MedlineCode>DAW</MedlineCode>
<NlmUniqueID>0147763</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Thallium Radioisotopes</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>34368-04-2</CASRegistryNumber>
<NameOfSubstance>Dobutamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrections>
<CommentIn>
<RefSource>Circulation. 1995 Dec 1;94(11):2681-4</RefSource>
</CommentIn>
<CommentIn>
<RefSource>Circulation. 1996 Dec 1;94(11):2674-80</RefSource>
</CommentIn>
<CommentIn>
<RefSource>Circulation. 1996 Dec 1;94(11):2685-8</RefSource>
</CommentIn>
<CommentIn>
<RefSource>Circulation. 1997 Oct 21;96(8):2740-2</RefSource>
</CommentIn>
</CommentsCorrections>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Aged</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Cell Survival</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Chronic Disease</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Circadian Rhythm</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Coronary Disease</Descriptor>
<SubHeading>physiopathology</SubHeading>
<SubHeading MajorTopicYN="Y">radionuclide imaging</SubHeading>
<SubHeading MajorTopicYN="Y">ultrasonography</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Dobutamine</Descriptor>
<SubHeading MajorTopicYN="Y">diagnostic use</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor MajorTopicYN="Y">Echocardiography</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Follow-Up Studies</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Heart</Descriptor>
<SubHeading MajorTopicYN="Y">radionuclide imaging</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Human</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Male</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Middle Age</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Myocardial Contraction</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Myocardial Revascularization</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Rest</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Systole</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Thallium Radioisotopes</Descriptor>
<SubHeading MajorTopicYN="Y">diagnostic use</SubHeading>
<SubHeading>pharmacokinetics</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Time Factors</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Ventricular Dysfunction, Left</Descriptor>
<SubHeading>radionuclide imaging</SubHeading>
<SubHeading>therapy</SubHeading>
<SubHeading>ultrasonography</SubHeading>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>98141546</MedlineID>
<PMID>9482442</PMID>
<DateCreated>
<Year>1998</Year>
<Month>03</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>1998</Year>
<Month>03</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0140-6736</ISSN>
<JournalIssue>
<Volume>351</Volume>
<Issue>9101</Issue>
<PubDate>
<Year>1998</Year>
<Month>Feb</Month>
<Day>14</Day>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>A woman with nodules in her lungs.</ArticleTitle>
<Pagination>
<MedlinePgn>494</MedlinePgn>
</Pagination>
<Affiliation>Department of Medicine, Turku University Central Hospital, Finland.</Affiliation>
<AuthorList>
<Author>
<LastName>Järveläinen</LastName>
<FirstName>H</FirstName>
<Initials>H</Initials>
</Author>
<Author>
<LastName>Vainionpää</LastName>
<FirstName>H</FirstName>
<Initials>H</Initials>
</Author>
<Author>
<LastName>Kuopio</LastName>
<FirstName>T</FirstName>
<Initials>T</Initials>
</Author>
<Author>
<LastName>Lehtonen</LastName>
<FirstName>A</FirstName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>ENGLAND</Country>
<MedlineTA>Lancet</MedlineTA>
<MedlineCode>L0S</MedlineCode>
<NlmUniqueID>2985213R</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Powders</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>7631-86-9</CASRegistryNumber>
<NameOfSubstance>Silicon Dioxide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrections>
<ErratumIn>
<RefSource>Lancet 1998 Jun 27;351(9120):1968</RefSource>
</ErratumIn>
<ErratumIn>
<RefSource>Lancet 1998 Mar 7;351(9104):760</RefSource>
</ErratumIn>
</CommentsCorrections>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Aged</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Case Report</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Female</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Human</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Naturopathy</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Powders</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Silicon Dioxide</Descriptor>
<SubHeading MajorTopicYN="Y">administration &#38; dosage</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Silicosis</Descriptor>
<SubHeading MajorTopicYN="Y">etiology</SubHeading>
<SubHeading MajorTopicYN="Y">radiography</SubHeading>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>98166671</MedlineID>
<PMID>9505772</PMID>
<DateCreated>
<Year>1998</Year>
<Month>03</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>1998</Year>
<Month>03</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0007-0912</ISSN>
<JournalIssue>
<Volume>80</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1998</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Myocardial ischaemia after coronary artery bypass grafting: early vs late extubation.</ArticleTitle>
<Pagination>
<MedlinePgn>20-5</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The technique of early extubation after coronary artery bypass grafting is increasing in popularity, but its safety and effect on myocardial ischaemia remain to be established. In a randomized, prospective study, patients undergoing routine elective coronary artery bypass grafting were managed with either early or late tracheal extubation. The incidence and severity of electrocardiographic myocardial ischaemia were compared. Data were analysed from 85 patients (43 early extubation; 42 late extubation). Median time to extubation was 110 min in the early extubation patients and 757 min in the late extubation patients. After correction for randomization bias, there were no significant differences between groups in ischaemic burden, maximal ST-segment deviation, incidence of ischaemia and area under the ST deviation-time curve (integral of ST deviation and time). Similarly, there were no differences between groups in postoperative creatine kinase MB-isoenzyme concentrations and duration of stay in the ICU or hospital. Therefore, this study provides evidence for the safety of early extubation after routine coronary artery bypass grafting.</AbstractText>
</Abstract>
<Affiliation>Cardiothoracic Centre Liverpool-NHS Trust.</Affiliation>
<AuthorList>
<Author>
<LastName>Berry</LastName>
<FirstName>P</FirstName>
<MiddleName>D</MiddleName>
<Initials>PD</Initials>
</Author>
<Author>
<LastName>Thomas</LastName>
<FirstName>S</FirstName>
<MiddleName>D</MiddleName>
<Initials>SD</Initials>
</Author>
<Author>
<LastName>Mahon</LastName>
<FirstName>S</FirstName>
<MiddleName>P</MiddleName>
<Initials>SP</Initials>
</Author>
<Author>
<LastName>Jackson</LastName>
<FirstName>M</FirstName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Fox</LastName>
<FirstName>M</FirstName>
<MiddleName>A</MiddleName>
<Initials>MA</Initials>
</Author>
<Author>
<LastName>Fabri</LastName>
<FirstName>B</FirstName>
<Initials>B</Initials>
</Author>
<Author>
<LastName>Weir</LastName>
<FirstName>W</FirstName>
<MiddleName>I</MiddleName>
<Initials>WI</Initials>
</Author>
<Author>
<LastName>Russell</LastName>
<FirstName>G</FirstName>
<MiddleName>N</MiddleName>
<Initials>GN</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Clinical Trial</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>ENGLAND</Country>
<MedlineTA>Br J Anaesth</MedlineTA>
<MedlineCode>AUO</MedlineCode>
<NlmUniqueID>0372541</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrections>
<ErratumIn>
<RefSource>Br J Anaesth 1998 Apr;80(4):572</RefSource>
</ErratumIn>
<ErratumIn>
<RefSource>Br J Anaesth 1998 Jul;81(1):111</RefSource>
</ErratumIn>
</CommentsCorrections>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Adult</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Aged</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Coronary Artery Bypass</Descriptor>
<SubHeading MajorTopicYN="Y">adverse effects</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Electrocardiography</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Female</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Human</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Intubation, Intratracheal</Descriptor>
<SubHeading MajorTopicYN="Y">methods</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Male</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Middle Age</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Myocardial Ischemia</Descriptor>
<SubHeading MajorTopicYN="Y">etiology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Postoperative Care</Descriptor>
<SubHeading MajorTopicYN="Y">methods</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Postoperative Period</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Prospective Studies</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Treatment Outcome</Descriptor>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>98236234</MedlineID>
<PMID>9575322</PMID>
<DateCreated>
<Year>1998</Year>
<Month>05</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>1998</Year>
<Month>05</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2001</Year>
<Month>03</Month>
<Day>23</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0002-838X</ISSN>
<JournalIssue>
<Volume>57</Volume>
<Issue>8</Issue>
<PubDate>
<Year>1998</Year>
<Month>Apr</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Lumbar spine stenosis: a common cause of back and leg pain.</ArticleTitle>
<Pagination>
<MedlinePgn>1825-34, 1839-40</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Lumbar spine stenosis most commonly affects the middle-aged and elderly population. Entrapment of the cauda equina roots by hypertrophy of the osseous and soft tissue structures surrounding the lumbar spinal canal is often associated with incapacitating pain in the back and lower extremities, difficulty ambulating, leg paresthesias and weakness and, in severe cases, bowel or bladder disturbances. The characteristic syndrome associated with lumbar stenosis is termed neurogenic intermittent claudication. This condition must be differentiated from true claudication, which is caused by atherosclerosis of the pelvofemoral vessels. Although many conditions may be associated with lumbar canal stenosis, most cases are idiopathic. Imaging of the lumbar spine performed with computed tomography or magnetic resonance imaging often demonstrates narrowing of the lumbar canal with compression of the cauda equina nerve roots by thickened posterior vertebral elements, facet joints, marginal osteophytes or soft tissue structures such as the ligamentum flavum or herniated discs. Treatment for symptomatic lumbar stenosis is usually surgical decompression. Medical treatment alternatives, such as bed rest, pain management and physical therapy, should be reserved for use in debilitated patients or patients whose surgical risk is prohibitive as a result of concomitant medical conditions.</AbstractText>
</Abstract>
<Affiliation>University Hospitals of Cleveland/Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation>
<AuthorList>
<Author>
<LastName>Alvarez</LastName>
<FirstName>J</FirstName>
<MiddleName>A</MiddleName>
<Initials>JA</Initials>
</Author>
<Author>
<LastName>Hardy</LastName>
<FirstName>R</FirstName>
<MiddleName>H</MiddleName>
<Initials>RH</Initials>
<Suffix>Jr</Suffix>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
<PublicationType>Review, Tutorial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Am Fam Physician</MedlineTA>
<MedlineCode>3BT</MedlineCode>
<NlmUniqueID>1272646</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrections>
<CommentIn>
<RefSource>Am Fam Physician. 1999 Jan 15;59(2):280, 283-4</RefSource>
</CommentIn>
</CommentsCorrections>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Diagnosis, Differential</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Human</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Low Back Pain</Descriptor>
<SubHeading MajorTopicYN="Y">etiology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Lumbosacral Region</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Pain</Descriptor>
<SubHeading MajorTopicYN="Y">etiology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Patient Education</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Spinal Stenosis</Descriptor>
<SubHeading MajorTopicYN="Y">complications</SubHeading>
<SubHeading MajorTopicYN="Y">diagnosis</SubHeading>
<SubHeading>physiopathology</SubHeading>
<SubHeading>therapy</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Teaching Materials</Descriptor>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>13</NumberOfReferences>
</MedlineCitation>
<MedlineCitation>
<MedlineID>98295397</MedlineID>
<PMID>9634358</PMID>
<DateCreated>
<Year>1998</Year>
<Month>06</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted>
<Year>1998</Year>
<Month>06</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0022-1899</ISSN>
<JournalIssue>
<Volume>177</Volume>
<Issue>6</Issue>
<PubDate>
<Year>1998</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Retraction: A rabbit model for human cytomeglovirus--induced chorioretinal disease (J Infect Dis 1993;168:336-44)</ArticleTitle>
<Pagination>
<MedlinePgn>1778</MedlinePgn>
</Pagination>
<AuthorList>
<Author>
<LastName>Dunkel</LastName>
<FirstName>E</FirstName>
<MiddleName>C</MiddleName>
<Initials>EC</Initials>
</Author>
<Author>
<LastName>Scheer</LastName>
<FirstName>D</FirstName>
<MiddleName>I</MiddleName>
<Initials>DI</Initials>
</Author>
<Author>
<LastName>Zhu</LastName>
<FirstName>Q</FirstName>
<Initials>Q</Initials>
</Author>
<Author>
<LastName>Whitley</LastName>
<FirstName>R</FirstName>
<MiddleName>J</MiddleName>
<Initials>RJ</Initials>
</Author>
<Author>
<LastName>Schaffer</LastName>
<FirstName>P</FirstName>
<MiddleName>A</MiddleName>
<Initials>PA</Initials>
</Author>
<Author>
<LastName>Pavan-Langston</LastName>
<FirstName>D</FirstName>
<Initials>D</Initials>
</Author>
<Author>
<LastName>Whitely</LastName>
<FirstName>R</FirstName>
<MiddleName>J</MiddleName>
<Initials>RJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Retraction of Publication</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>J Infect Dis</MedlineTA>
<MedlineCode>IH3</MedlineCode>
<NlmUniqueID>0413675</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrections>
<ErratumIn>
<RefSource>J Infect Dis 1998 Aug;178(2):601</RefSource>
<Note>Whitely RJ[corrected to Whitley RJ]</Note>
</ErratumIn>
<RetractionOf>
<RefSource>Dunkel EC, de Freitas D, Scheer DI, Siegel ML, Zhu Q, Whitley RJ, Schaffer PA, Pavan-Langston D. J Infect Dis 1993 Aug;168(2):336-44</RefSource>
</RetractionOf>
</CommentsCorrections>
</MedlineCitation>
<MedlineCitation>
<MedlineID>98288599</MedlineID>
<PMID>9626910</PMID>
<DateCreated>
<Year>1998</Year>
<Month>08</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>1998</Year>
<Month>08</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0047-1828</ISSN>
<JournalIssue>
<Volume>62</Volume>
<Issue>5</Issue>
<PubDate>
<Year>1998</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Hepatitis C virus infection and heart diseases: a multicenter study in Japan.</ArticleTitle>
<Pagination>
<MedlinePgn>389-91</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>As a collaborative research project of the Committees for the Study of Idiopathic Cardiomyopathy, a questionnaire was sent out to 19 medical institutions in Japan in order to examine the possible association between hepatitis C virus (HCV) infection and cardiomyopathies. Hepatitis C virus antibody was found in 74 of 697 patients (10.6%) with hypertrophic cardiomyopathy (mean age, 57.7 years) and in 42 of 663 patients (6.3%) with dilated cardiomyopathy (mean age, 56.5 years); these prevalences were significantly higher than that found in volunteer blood donors in Japan (2.4%, 50-59 years of age, each p&#60;0.0001). The prevalence was significantly higher in patients suffering from hypertrophic cardiomyopathy as opposed to those with dilated cardiomyopathy (p&#60;0.01). The presence of HCV antibody was detected in 650 of 11,967 patients (5.4%) patients seeking care in 5 academic hospitals. Various cardiac abnormalities were found among these patients, arrhythmias being the most frequent. These observations suggest that HCV infection is an important cause of a variety of otherwise unexplained heart diseases.</AbstractText>
</Abstract>
<Affiliation>Kyoto University, Japan.</Affiliation>
<AuthorList CompleteYN="N">
<Author>
<LastName>Matsumori</LastName>
<FirstName>A</FirstName>
<Initials>A</Initials>
</Author>
<Author>
<LastName>Ohashi</LastName>
<FirstName>N</FirstName>
<Initials>N</Initials>
</Author>
<Author>
<LastName>Hasegawa</LastName>
<FirstName>K</FirstName>
<Initials>K</Initials>
</Author>
<Author>
<LastName>Sasayama</LastName>
<FirstName>S</FirstName>
<Initials>S</Initials>
</Author>
<Author>
<LastName>Eto</LastName>
<FirstName>T</FirstName>
<Initials>T</Initials>
</Author>
<Author>
<LastName>Imaizumi</LastName>
<FirstName>T</FirstName>
<Initials>T</Initials>
</Author>
<Author>
<LastName>Izumi</LastName>
<FirstName>T</FirstName>
<Initials>T</Initials>
</Author>
<Author>
<LastName>Kawamura</LastName>
<FirstName>K</FirstName>
<Initials>K</Initials>
</Author>
<Author>
<LastName>Kawana</LastName>
<FirstName>M</FirstName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Kimura</LastName>
<FirstName>A</FirstName>
<Initials>A</Initials>
</Author>
<Author>
<LastName>Kitabatake</LastName>
<FirstName>A</FirstName>
<Initials>A</Initials>
</Author>
<Author>
<LastName>Matsuzaki</LastName>
<FirstName>M</FirstName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Nagai</LastName>
<FirstName>R</FirstName>
<Initials>R</Initials>
</Author>
<Author>
<LastName>Tanaka</LastName>
<FirstName>H</FirstName>
<Initials>H</Initials>
</Author>
<Author>
<LastName>Hiroe</LastName>
<FirstName>M</FirstName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Hori</LastName>
<FirstName>M</FirstName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Inoko</LastName>
<FirstName>H</FirstName>
<Initials>H</Initials>
</Author>
<Author>
<LastName>Seko</LastName>
<FirstName>Y</FirstName>
<Initials>Y</Initials>
</Author>
<Author>
<LastName>Sekiguchi</LastName>
<FirstName>M</FirstName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Shimotohno</LastName>
<FirstName>K</FirstName>
<Initials>K</Initials>
</Author>
<Author>
<LastName>Sugishita</LastName>
<FirstName>Y</FirstName>
<Initials>Y</Initials>
</Author>
<Author>
<LastName>Takeda</LastName>
<FirstName>N</FirstName>
<Initials>N</Initials>
</Author>
<Author>
<LastName>Takihara</LastName>
<FirstName>K</FirstName>
<Initials>K</Initials>
</Author>
<Author>
<LastName>Tanaka</LastName>
<FirstName>M</FirstName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Yokoyama</LastName>
<FirstName>M</FirstName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Multicenter Study</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>AUSTRALIA</Country>
<MedlineTA>Jpn Circ J</MedlineTA>
<MedlineCode>KGN</MedlineCode>
<NlmUniqueID>7806868</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Hepatitis C Antibodies</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Heart</Descriptor>
<SubHeading>virology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Heart Diseases</Descriptor>
<SubHeading MajorTopicYN="Y">epidemiology</SubHeading>
<SubHeading>etiology</SubHeading>
<SubHeading MajorTopicYN="Y">virology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Hepatitis C</Descriptor>
<SubHeading MajorTopicYN="Y">complications</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Hepatitis C Antibodies</Descriptor>
<SubHeading>blood</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Hepatitis C-Like Viruses</Descriptor>
<SubHeading>immunology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Human</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Japan</Descriptor>
<SubHeading>epidemiology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Middle Age</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Myocardial Diseases</Descriptor>
<SubHeading>epidemiology</SubHeading>
<SubHeading>etiology</SubHeading>
<SubHeading>virology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Myocardium</Descriptor>
<SubHeading>immunology</SubHeading>
<SubHeading>pathology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Prevalence</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Questionnaires</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Support, Non-U.S. Gov't</Descriptor>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>98288859</MedlineID>
<PMID>9627170</PMID>
<DateCreated>
<Year>1998</Year>
<Month>08</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted>
<Year>1998</Year>
<Month>08</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>1435-2443</ISSN>
<JournalIssue>
<Volume>383</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1998</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Outcome of patients with sepsis and septic shock after ICU treatment.</ArticleTitle>
<Pagination>
<MedlinePgn>44-8</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>OBJECTIVE: Today, sepsis syndrome is the leading cause of death in adult, non-coronary intensive care units (ICUs) and is of great clinical importance. The purpose of this review was to evaluate recent prospective studies concerning the short- and long-term prognosis of patients suffering from systemic inflammatory-response syndrome (SIRS), sepsis, severe sepsis and septic shock. It has been shown in multicentre prospective surveys that 1% and 0.3% of all patients admitted to hospitals suffer, respectively, from bacteraemia alone and bacteraemia with severe sepsis. This rate increases, of course, when only admissions to the ICUs are considered: the above-mentioned rates increase then by a factor of 8 and 30, respectively. Thus, approximately 10% of patients in the ICU suffer from sepsis, 6% from severe sepsis and 2-3% from septic shock. SIRS occurs more frequently and its occurrence ranges from 40% to 70% of all patients admitted to ICUs. Thereby, 40-70% suffering from SIRS progress to a more severe septic-disease state. The overall prognosis is still poor, despite the recent advances in ICU treatment. The mortality rate of SIRS ranges from 6% to 7% and in septic shock amounts to over 50%. In particular, abdominal sepsis exhibits the highest mortality rate with 72%. The long-term prognosis is equally poor; only approximately 30% survived the first year after hospital admission. CONCLUSION: The prognosis of sepsis and septic shock remains poor, despite the advances in ICU treatment. Although prognostic factors have been identified for some patients, groups have not yet been able to identify the immediate or long-term prognosis for the majority of these septic patients.</AbstractText>
</Abstract>
<Affiliation>Department of General Surgery, University of Ulm, Germany.</Affiliation>
<AuthorList>
<Author>
<LastName>Schoenberg</LastName>
<FirstName>M</FirstName>
<MiddleName>H</MiddleName>
<Initials>MH</Initials>
</Author>
<Author>
<LastName>Weiss</LastName>
<FirstName>M</FirstName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Radermacher</LastName>
<FirstName>P</FirstName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
<PublicationType>Review, Tutorial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>GERMANY</Country>
<MedlineTA>Langenbecks Arch Surg</MedlineTA>
<MedlineCode>CW4</MedlineCode>
<NlmUniqueID>9808285</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Adult</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Bacteremia</Descriptor>
<SubHeading MajorTopicYN="Y">mortality</SubHeading>
<SubHeading>therapy</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Cause of Death</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Female</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Human</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor MajorTopicYN="Y">Intensive Care</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Male</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Prognosis</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Prospective Studies</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Sepsis Syndrome</Descriptor>
<SubHeading MajorTopicYN="Y">mortality</SubHeading>
<SubHeading>therapy</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Shock, Septic</Descriptor>
<SubHeading MajorTopicYN="Y">mortality</SubHeading>
<SubHeading>therapy</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Surgical Wound Infection</Descriptor>
<SubHeading MajorTopicYN="Y">mortality</SubHeading>
<SubHeading>therapy</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Survival Rate</Descriptor>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>21</NumberOfReferences>
</MedlineCitation>
<MedlineCitation>
<MedlineID>99103180</MedlineID>
<PMID>9885794</PMID>
<DateCreated>
<Year>1999</Year>
<Month>03</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>03</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0893-133X</ISSN>
<JournalIssue>
<Volume>20</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1999</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Antipsychotic potential of CCK-based treatments: an assessment using the prepulse inhibition model of psychosis.</ArticleTitle>
<Pagination>
<MedlinePgn>141-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Systemic injections of cholecystokinin (CCK), a "gut-brain" peptide, have been shown to modulate brain dopamine function and produce neuroleptic-like effects on such dopamine-regulated behaviors as locomotor activity. However, clinical trials of CCK agonists in schizophrenia patients showed mixed results. To re-examine the antipsychotic potential of CCK-based treatments, we examined systemic injections of CCK analogs in an animal model with strong face and construct validity for sensorimotor-gating deficits seen in schizophrenia patients and with strong predictive validity for antipsychotic drug activity. Prepulse inhibition (PPI) occurs when a weak acoustic lead stimulus ("prepulse") inhibits the startle response to a sudden loud sound ("pulse"). PPI is significantly reduced in schizophrenia patients and rats treated with dopamine agonists. Antipsychotics reverse decreased PPI in rats to a degree highly correlated with their clinical efficacy. Subcutaneous (s.c.) injections of caerulein (10 micrograms/kg) a mixed CCKA/B agonist, partially reversed amphetamine-induced reduction of PPI; whereas, s.c. haloperidol (0.5 mg/kg) totally reversed amphetamine-induced disruption of PPI. Caerulein's effect on PPI was blocked by pretreatment with a CCKA antagonist (devazepide) but not a CCKB antagonist (L-365,260). CCK-4, a preferential CCKB agonist, had no significant effect on PPI. These results suggest that caerulein produces a weak neuroleptic-like effect on PPI that is mediated by stimulation of CCKA receptors. Possible circuities in this effect are discussed. In a separate experiment, s.c. caerulein produced to a more potent neuroleptic-like profile on amphetamine-induced hyperlocomotion, suggesting that selection of preclinical paradigms may be important in evaluating the antipsychotic potential of CCK-based treatments.</AbstractText>
</Abstract>
<Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla 92093-8620, USA.</Affiliation>
<AuthorList>
<Author>
<LastName>Feifel</LastName>
<FirstName>D</FirstName>
<Initials>D</Initials>
</Author>
<Author>
<LastName>Reza</LastName>
<FirstName>T</FirstName>
<Initials>T</Initials>
</Author>
<Author>
<LastName>Robeck</LastName>
<FirstName>S</FirstName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Neuropsychopharmacology</MedlineTA>
<MedlineCode>ADQ</MedlineCode>
<NlmUniqueID>8904907</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Antipsychotic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Antipsychotic Agents, Butyrophenone</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Gastrointestinal Agents</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Receptors, Cholecystokinin</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>17650-98-5</CASRegistryNumber>
<NameOfSubstance>Caerulein</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>1947-37-1</CASRegistryNumber>
<NameOfSubstance>Tetragastrin</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>52-86-8</CASRegistryNumber>
<NameOfSubstance>Haloperidol</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>9011-97-6</CASRegistryNumber>
<NameOfSubstance>Cholecystokinin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Animal</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Antipsychotic Agents</Descriptor>
<SubHeading MajorTopicYN="Y">therapeutic use</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Antipsychotic Agents, Butyrophenone</Descriptor>
<SubHeading>administration &#38; dosage</SubHeading>
<SubHeading>therapeutic use</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Behavior, Animal</Descriptor>
<SubHeading>drug effects</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Caerulein</Descriptor>
<SubHeading MajorTopicYN="Y">therapeutic use</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Cholecystokinin</Descriptor>
<SubHeading MajorTopicYN="Y">physiology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Gastrointestinal Agents</Descriptor>
<SubHeading MajorTopicYN="Y">therapeutic use</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Haloperidol</Descriptor>
<SubHeading>administration &#38; dosage</SubHeading>
<SubHeading>therapeutic use</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Injections, Subcutaneous</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Male</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Motor Activity</Descriptor>
<SubHeading>drug effects</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Psychotic Disorders</Descriptor>
<SubHeading MajorTopicYN="Y">drug therapy</SubHeading>
<SubHeading>psychology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Rats</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Rats, Sprague-Dawley</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Receptors, Cholecystokinin</Descriptor>
<SubHeading>antagonists &#38; inhibitors</SubHeading>
<SubHeading>drug effects</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Startle Reaction</Descriptor>
<SubHeading>drug effects</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Support, Non-U.S. Gov't</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Tetragastrin</Descriptor>
<SubHeading>antagonists &#38; inhibitors</SubHeading>
<SubHeading>pharmacology</SubHeading>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>99078569</MedlineID>
<PMID>9861576</PMID>
<DateCreated>
<Year>1999</Year>
<Month>03</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>03</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0268-1315</ISSN>
<JournalIssue>
<Volume>13</Volume>
<Issue>6</Issue>
<PubDate>
<Year>1998</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients.</ArticleTitle>
<Pagination>
<MedlinePgn>263-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Selective serotonin reuptake inhibitors (SSRIs) are the 'new' drugs of first choice for the treatment of depression in the older patient. Systematic studies on the effects of SSRIs on cardiac function are scarce, despite the high prevalence of cardiac disorders in the older depressed patient. This is a study which systematically assessed cardiac function by echocardiography in middle-aged and elderly depressed patients treated with SSRI. In a double-blind randomized trial, 20 patients were assigned to receive fluvoxamine 100 mg/day [corrected] or fluoxetine 20 mg/day [corrected] for 6 weeks. Cardiac function was assessed by left ventricle ejection fraction, aortic flow integral and early or passive/late or active mitral inflow, and electrocardiography. Neither SSRI significantly affected cardiac function. Compared with patients without a history of myocardial infarction and/or hypertension, patients with such a history showed a significant improvement in left ventricular ejection fraction. Despite our small study sample, these data indicate that both fluoxetine and fluvoxamine do not affect cardiac function adversely.</AbstractText>
</Abstract>
<Affiliation>Department of Psychiatry, Maastricht University Hospital, The Netherlands.</Affiliation>
<AuthorList>
<Author>
<LastName>Strik</LastName>
<FirstName>J</FirstName>
<MiddleName>J</MiddleName>
<Initials>JJ</Initials>
</Author>
<Author>
<LastName>Honig</LastName>
<FirstName>A</FirstName>
<Initials>A</Initials>
</Author>
<Author>
<LastName>Lousberg</LastName>
<FirstName>R</FirstName>
<Initials>R</Initials>
</Author>
<Author>
<LastName>Cheriex</LastName>
<FirstName>E</FirstName>
<MiddleName>C</MiddleName>
<Initials>EC</Initials>
</Author>
<Author>
<LastName>Van Praag</LastName>
<FirstName>H</FirstName>
<MiddleName>M</MiddleName>
<Initials>HM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Clinical Trial</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>ENGLAND</Country>
<MedlineTA>Int Clin Psychopharmacol</MedlineTA>
<MedlineCode>ICP</MedlineCode>
<NlmUniqueID>8609061</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Serotonin Uptake Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>54739-18-3</CASRegistryNumber>
<NameOfSubstance>Fluvoxamine</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>54910-89-3</CASRegistryNumber>
<NameOfSubstance>Fluoxetine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrections>
<ErratumIn>
<RefSource>Int Clin Psychopharmacol 1999 Mar;14(2):138</RefSource>
</ErratumIn>
</CommentsCorrections>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Aged</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Aged, 80 and over</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Cardiovascular Diseases</Descriptor>
<SubHeading MajorTopicYN="Y">chemically induced</SubHeading>
<SubHeading>physiopathology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Comparative Study</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Depressive Disorder</Descriptor>
<SubHeading MajorTopicYN="Y">complications</SubHeading>
<SubHeading>drug therapy</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Double-Blind Method</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Echocardiography</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Electrocardiography</Descriptor>
<SubHeading>drug effects</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Female</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Fluoxetine</Descriptor>
<SubHeading MajorTopicYN="Y">adverse effects</SubHeading>
<SubHeading>therapeutic use</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Fluvoxamine</Descriptor>
<SubHeading MajorTopicYN="Y">adverse effects</SubHeading>
<SubHeading>therapeutic use</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Human</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Male</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Middle Age</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Serotonin Uptake Inhibitors</Descriptor>
<SubHeading MajorTopicYN="Y">adverse effects</SubHeading>
<SubHeading>therapeutic use</SubHeading>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>99204308</MedlineID>
<PMID>10188493</PMID>
<DateCreated>
<Year>1999</Year>
<Month>04</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>04</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>1354-5760</ISSN>
<JournalIssue>
<Volume>5</Volume>
<Issue>8</Issue>
<PubDate>
<MedlineDate>1998 Dec-1999 Jan</MedlineDate>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Women's health osteopathy: an alternative view.</ArticleTitle>
<Pagination>
<MedlinePgn>6-9</MedlinePgn>
</Pagination>
<AuthorList>
<Author>
<LastName>Hyne</LastName>
<FirstName>J</FirstName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>ENGLAND</Country>
<MedlineTA>Nurs Manag (Harrow)</MedlineTA>
<MedlineCode>B2K</MedlineCode>
<NlmUniqueID>9433248</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>N</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Female</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Great Britain</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Human</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Osteopathic Medicine</Descriptor>
<SubHeading MajorTopicYN="Y">methods</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>State Medicine</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor MajorTopicYN="Y">Women's Health</Descriptor>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>99201558</MedlineID>
<PMID>10101342</PMID>
<DateCreated>
<Year>1999</Year>
<Month>04</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>04</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0733-8627</ISSN>
<JournalIssue>
<Volume>17</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1999</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Evaluation of the patient with extremity trauma: an evidence based approach.</ArticleTitle>
<Pagination>
<MedlinePgn>77-95, viii</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>This article reviews relevant literature to provide evidence based guidelines for the evaluation of patients with extremity trauma in the emergency department. The development of clinical decision rules for extremity trauma in the ankle and knee, and guidelines for obtaining postreduction radiographs of shoulder dislocations and nursemaid's elbows are discussed.</AbstractText>
</Abstract>
<Affiliation>Division of Emergency Medicine, Northwestern University Medical School, Chicago, Illinois, USA.</Affiliation>
<AuthorList>
<Author>
<LastName>Kaufman</LastName>
<FirstName>D</FirstName>
<Initials>D</Initials>
</Author>
<Author>
<LastName>Leung</LastName>
<FirstName>J</FirstName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Emerg Med Clin North Am</MedlineTA>
<MedlineCode>EGD</MedlineCode>
<NlmUniqueID>8219565</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Ankle Injuries</Descriptor>
<SubHeading>etiology</SubHeading>
<SubHeading>radiography</SubHeading>
<SubHeading>therapy</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Decision Support Techniques</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor MajorTopicYN="Y">Emergencies</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Extremities</Descriptor>
<SubHeading MajorTopicYN="Y">injuries</SubHeading>
<SubHeading>radiography</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Fractures</Descriptor>
<SubHeading>etiology</SubHeading>
<SubHeading>radiography</SubHeading>
<SubHeading>therapy</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Human</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Knee Injuries</Descriptor>
<SubHeading>etiology</SubHeading>
<SubHeading>radiography</SubHeading>
<SubHeading>therapy</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Practice Guidelines</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Shoulder Dislocation</Descriptor>
<SubHeading>etiology</SubHeading>
<SubHeading>radiography</SubHeading>
<SubHeading>therapy</SubHeading>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>99128588</MedlineID>
<PMID>9929727</PMID>
<DateCreated>
<Year>1999</Year>
<Month>04</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>04</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0300-2896</ISSN>
<JournalIssue>
<Volume>34</Volume>
<Issue>11</Issue>
<PubDate>
<Year>1998</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>[Tobacco control in children, adolescents and young people: knowledge, prevention and action]</ArticleTitle>
<Pagination>
<MedlinePgn>564</MedlinePgn>
</Pagination>
<AuthorList>
<Author>
<LastName>de Granda Orive</LastName>
<FirstName>J</FirstName>
<MiddleName>I</MiddleName>
<Initials>JI</Initials>
</Author>
<Author>
<LastName>Peña Miguel</LastName>
<FirstName>T</FirstName>
<Initials>T</Initials>
</Author>
<Author>
<LastName>Morato Arnáiz</LastName>
<FirstName>A</FirstName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>spa</Language>
<PublicationTypeList>
<PublicationType>Comment</PublicationType>
<PublicationType>Letter</PublicationType>
</PublicationTypeList>
<VernacularTitle>La lucha contra el tabaco en los niños, adolescentes y jóvenes: conocimiento, prevención y actuación.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>SPAIN</Country>
<MedlineTA>Arch Bronconeumol</MedlineTA>
<MedlineCode>B0Y</MedlineCode>
<NlmUniqueID>0354720</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrections>
<CommentOn>
<RefSource>Arch Bronconeumol. 1998 Apr;34(4):199-203</RefSource>
</CommentOn>
</CommentsCorrections>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Adolescence</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Adult</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Child</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Female</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Human</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Knowledge, Attitudes, Practice</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Male</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Smoking</Descriptor>
<SubHeading MajorTopicYN="Y">prevention &#38; control</SubHeading>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>99183733</MedlineID>
<PMID>10083987</PMID>
<DateCreated>
<Year>1999</Year>
<Month>05</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>05</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0832-610X</ISSN>
<JournalIssue>
<Volume>46</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1999</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Complete airway obstruction.</ArticleTitle>
<Pagination>
<MedlinePgn>99-104</MedlinePgn>
</Pagination>
<AuthorList>
<Author>
<LastName>Crosby</LastName>
<FirstName>E</FirstName>
<MiddleName>T</MiddleName>
<Initials>ET</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<Language>fre</Language>
<PublicationTypeList>
<PublicationType>Comment</PublicationType>
<PublicationType>Editorial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>CANADA</Country>
<MedlineTA>Can J Anaesth</MedlineTA>
<MedlineCode>C8L</MedlineCode>
<NlmUniqueID>8701709</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Anesthetics, Local</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrections>
<CommentOn>
<RefSource>Can J Anaesth. 1999 Feb;46(2):176-8</RefSource>
</CommentOn>
</CommentsCorrections>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Airway Obstruction</Descriptor>
<SubHeading MajorTopicYN="Y">etiology</SubHeading>
<SubHeading>surgery</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Anesthesiology</Descriptor>
<SubHeading>education</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Anesthetics, Local</Descriptor>
<SubHeading>administration &#38; dosage</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Cervical Vertebrae</Descriptor>
<SubHeading>injuries</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Conscious Sedation</Descriptor>
<SubHeading>adverse effects</SubHeading>
<SubHeading>methods</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Human</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Intubation, Intratracheal</Descriptor>
<SubHeading MajorTopicYN="Y">adverse effects</SubHeading>
<SubHeading>instrumentation</SubHeading>
<SubHeading>methods</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Laryngoscopes</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Laryngoscopy</Descriptor>
<SubHeading>adverse effects</SubHeading>
<SubHeading>instrumentation</SubHeading>
<SubHeading>methods</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Tracheostomy</Descriptor>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>99199226</MedlineID>
<PMID>10097079</PMID>
<DateCreated>
<Year>1999</Year>
<Month>05</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>05</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0027-8424</ISSN>
<JournalIssue>
<Volume>96</Volume>
<Issue>7</Issue>
<PubDate>
<Year>1999</Year>
<Month>Mar</Month>
<Day>30</Day>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Thermal adaptation analyzed by comparison of protein sequences from mesophilic and extremely thermophilic Methanococcus species.</ArticleTitle>
<Pagination>
<MedlinePgn>3578-83</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The genome sequence of the extremely thermophilic archaeon Methanococcus jannaschii provides a wealth of data on proteins from a thermophile. In this paper, sequences of 115 proteins from M. jannaschii are compared with their homologs from mesophilic Methanococcus species. Although the growth temperatures of the mesophiles are about 50 degrees C below that of M. jannaschii, their genomic G+C contents are nearly identical. The properties most correlated with the proteins of the thermophile include higher residue volume, higher residue hydrophobicity, more charged amino acids (especially Glu, Arg, and Lys), and fewer uncharged polar residues (Ser, Thr, Asn, and Gln). These are recurring themes, with all trends applying to 83-92% of the proteins for which complete sequences were available. Nearly all of the amino acid replacements most significantly correlated with the temperature change are the same relatively conservative changes observed in all proteins, but in the case of the mesophile/thermophile comparison there is a directional bias. We identify 26 specific pairs of amino acids with a statistically significant (P &#60; 0.01) preferred direction of replacement.</AbstractText>
</Abstract>
<Affiliation>Department of Microbiology, University of Illinois, B103 Chemical and Life Sciences Laboratory, 601 South Goodwin Avenue, Urbana, IL 61801, USA.</Affiliation>
<AuthorList>
<Author>
<LastName>Haney</LastName>
<FirstName>P</FirstName>
<MiddleName>J</MiddleName>
<Initials>PJ</Initials>
</Author>
<Author>
<LastName>Badger</LastName>
<FirstName>J</FirstName>
<MiddleName>H</MiddleName>
<Initials>JH</Initials>
</Author>
<Author>
<LastName>Buldak</LastName>
<FirstName>G</FirstName>
<MiddleName>L</MiddleName>
<Initials>GL</Initials>
</Author>
<Author>
<LastName>Reich</LastName>
<FirstName>C</FirstName>
<MiddleName>I</MiddleName>
<Initials>CI</Initials>
</Author>
<Author>
<LastName>Woese</LastName>
<FirstName>C</FirstName>
<MiddleName>R</MiddleName>
<Initials>CR</Initials>
</Author>
<Author>
<LastName>Olsen</LastName>
<FirstName>G</FirstName>
<MiddleName>J</MiddleName>
<Initials>GJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="N">
<DataBank>
<DataBankName>GENBANK</DataBankName>
<AccessionNumberList>
<AccessionNumber>AF078607</AccessionNumber>
<AccessionNumber>AF078608</AccessionNumber>
<AccessionNumber>AF078609</AccessionNumber>
<AccessionNumber>AF078610</AccessionNumber>
<AccessionNumber>AF078611</AccessionNumber>
<AccessionNumber>AF078612</AccessionNumber>
<AccessionNumber>AF078613</AccessionNumber>
<AccessionNumber>AF078614</AccessionNumber>
<AccessionNumber>AF078615</AccessionNumber>
<AccessionNumber>AF078616</AccessionNumber>
<AccessionNumber>AF078617</AccessionNumber>
<AccessionNumber>AF078618</AccessionNumber>
<AccessionNumber>AF078619</AccessionNumber>
<AccessionNumber>AF078620</AccessionNumber>
<AccessionNumber>AF078621</AccessionNumber>
<AccessionNumber>AF078622</AccessionNumber>
<AccessionNumber>AF078623</AccessionNumber>
<AccessionNumber>AF078624</AccessionNumber>
<AccessionNumber>AF078625</AccessionNumber>
<AccessionNumber>AF078626</AccessionNumber>
<AccessionNumber>AF078627</AccessionNumber>
<AccessionNumber>AF078628</AccessionNumber>
<AccessionNumber>AF078629</AccessionNumber>
<AccessionNumber>AF078630</AccessionNumber>
<AccessionNumber>AF078631</AccessionNumber>
<AccessionNumber>AF078632</AccessionNumber>
<AccessionNumber>AF078633</AccessionNumber>
<AccessionNumber>AF078634</AccessionNumber>
<AccessionNumber>AF078635</AccessionNumber>
<AccessionNumber>AF078636</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList>
<Grant>
<GrantID>GM07283</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS</Agency>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<MedlineCode>PV3</MedlineCode>
<NlmUniqueID>7505876</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Bacterial Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Acclimatization</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Amino Acid Sequence</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Amino Acid Substitution</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Bacterial Proteins</Descriptor>
<SubHeading MajorTopicYN="Y">chemistry</SubHeading>
<SubHeading>genetics</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Comparative Study</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Methanococcus</Descriptor>
<SubHeading MajorTopicYN="Y">genetics</SubHeading>
<SubHeading MajorTopicYN="Y">metabolism</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Molecular Sequence Data</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Protein Conformation</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Species Specificity</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Support, U.S. Gov't, Non-P.H.S.</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Support, U.S. Gov't, P.H.S.</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Temperature</Descriptor>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>99207838</MedlineID>
<PMID>10192114</PMID>
<DateCreated>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0031-7144</ISSN>
<JournalIssue>
<Volume>54</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1999</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Antimicrobial activity of some Nepalese medicinal plants.</ArticleTitle>
<Pagination>
<MedlinePgn>232-4</MedlinePgn>
</Pagination>
<Affiliation>Institute of Pharmacy, Ernst-Moritz-Arndt-University, Greifswald, Germany.</Affiliation>
<AuthorList>
<Author>
<LastName>Rajbhandari</LastName>
<FirstName>M</FirstName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Schöpke</LastName>
<FirstName>T</FirstName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>GERMANY</Country>
<MedlineTA>Pharmazie</MedlineTA>
<MedlineCode>P4D</MedlineCode>
<NlmUniqueID>9800766</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Anti-Infective Agents</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Plant Extracts</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Anti-Infective Agents</Descriptor>
<SubHeading MajorTopicYN="Y">isolation &#38; purification</SubHeading>
<SubHeading>pharmacology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Gram-Positive Bacteria</Descriptor>
<SubHeading>drug effects</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Microbial Sensitivity Tests</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Nepal</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Plant Extracts</Descriptor>
<SubHeading>pharmacology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Plants, Medicinal</Descriptor>
<SubHeading MajorTopicYN="Y">chemistry</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Support, Non-U.S. Gov't</Descriptor>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>99207839</MedlineID>
<PMID>10192115</PMID>
<DateCreated>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0031-7144</ISSN>
<JournalIssue>
<Volume>54</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1999</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Different kinetics of hydroquinone depletion in various medicinal plant tissue cultures producing arbutin.</ArticleTitle>
<Pagination>
<MedlinePgn>234-5</MedlinePgn>
</Pagination>
<Affiliation>Department of Pharmaceutical Botany and Ecology, Faculty of Pharmacy, Charles University, Hradec Králové, Czech Republic.</Affiliation>
<AuthorList>
<Author>
<LastName>Jahodár</LastName>
<FirstName>L</FirstName>
<Initials>L</Initials>
</Author>
<Author>
<LastName>Dusková</LastName>
<FirstName>J</FirstName>
<Initials>J</Initials>
</Author>
<Author>
<LastName>Polásek</LastName>
<FirstName>M</FirstName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Papugová</LastName>
<FirstName>P</FirstName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>GERMANY</Country>
<MedlineTA>Pharmazie</MedlineTA>
<MedlineCode>P4D</MedlineCode>
<NlmUniqueID>9800766</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Hydroquinones</NameOfSubstance>
</Chemical>
<Chemical>
<CASRegistryNumber>497-76-7</CASRegistryNumber>
<NameOfSubstance>Arbutin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Arbutin</Descriptor>
<SubHeading>analysis</SubHeading>
<SubHeading MajorTopicYN="Y">biosynthesis</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Flow Injection Analysis</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Hydroquinones</Descriptor>
<SubHeading>analysis</SubHeading>
<SubHeading MajorTopicYN="Y">chemistry</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Kinetics</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Plants, Medicinal</Descriptor>
<SubHeading MajorTopicYN="Y">metabolism</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Tissue Culture</Descriptor>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>99260591</MedlineID>
<PMID>10331748</PMID>
<DateCreated>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0031-9023</ISSN>
<JournalIssue>
<Volume>79</Volume>
<Issue>5</Issue>
<PubDate>
<Year>1999</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Looking for the Forrest.</ArticleTitle>
<Pagination>
<MedlinePgn>454-5</MedlinePgn>
</Pagination>
<AuthorList>
<Author>
<LastName>Rothstein</LastName>
<FirstName>J</FirstName>
<MiddleName>M</MiddleName>
<Initials>JM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Editorial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Phys Ther</MedlineTA>
<MedlineCode>P6W</MedlineCode>
<NlmUniqueID>0022623</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<Descriptor MajorTopicYN="Y">Empathy</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Human</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Knowledge</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Physical Therapy</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor MajorTopicYN="Y">Professional-Patient Relations</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor MajorTopicYN="Y">Social Change</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Violence</Descriptor>
<SubHeading MajorTopicYN="Y">psychology</SubHeading>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>99260592</MedlineID>
<PMID>10331749</PMID>
<DateCreated>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>06</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0031-9023</ISSN>
<JournalIssue>
<Volume>79</Volume>
<Issue>5</Issue>
<PubDate>
<Year>1999</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Effects of side lying on lung function in older individuals.</ArticleTitle>
<Pagination>
<MedlinePgn>456-66</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>BACKGROUND AND PURPOSE: Body positioning exerts a strong effect on pulmonary function, but its effect on other components of the oxygen transport pathway are less well understood, especially the effects of side-lying positions. This study investigated the interrelationships between side-lying positions and indexes of lung function such as spirometry, alveolar diffusing capacity, and inhomogeneity of ventilation in older individuals. SUBJECTS AND METHODS: Nineteen nonsmoking subjects (mean age=62.8 years, SD=6.8, range=50-74) with no history of cardiac or pulmonary disease were tested over 2 sessions. The test positions were sitting and left side lying in one session and sitting and right side lying in the other session. In each of the positions, forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), single-breath pulmonary diffusing capacity (DLCO/VA), and the slope of phase III (DN2%/L) of the single-breath nitrogen washout test to determine inhomogeneity of ventilation were measured. RESULTS: Compared with measurements obtained in the sitting position, FVC and FEV1 were decreased equally in the side-lying positions, but no change was observed in DLCO/VA or DN2%/L. CONCLUSION AND DISCUSSION: Side-lying positions resulted in decreases in FVC and FEV1, which is consistent with the well-documented effects of the supine position. These findings further support the need for prescriptive rather than routine body positioning of patients with risks of cardiopulmonary compromise and the need to use upright positions in which lung volumes and capacities are maximized.</AbstractText>
</Abstract>
<Affiliation>Family Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada.</Affiliation>
<AuthorList>
<Author>
<LastName>Manning</LastName>
<FirstName>F</FirstName>
<Initials>F</Initials>
</Author>
<Author>
<LastName>Dean</LastName>
<FirstName>E</FirstName>
<Initials>E</Initials>
</Author>
<Author>
<LastName>Ross</LastName>
<FirstName>J</FirstName>
<Initials>J</Initials>
</Author>
<Author>
<LastName>Abboud</LastName>
<FirstName>R</FirstName>
<MiddleName>T</MiddleName>
<Initials>RT</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Phys Ther</MedlineTA>
<MedlineCode>P6W</MedlineCode>
<NlmUniqueID>0022623</NlmUniqueID>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<Descriptor>Aged</Descriptor>
<SubHeading MajorTopicYN="Y">physiology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Breath Tests</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Female</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Forced Expiratory Volume</Descriptor>
<SubHeading MajorTopicYN="Y">physiology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Heart Diseases</Descriptor>
<SubHeading>prevention &#38; control</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Human</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Lung Diseases</Descriptor>
<SubHeading>prevention &#38; control</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Male</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Middle Age</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Posture</Descriptor>
<SubHeading MajorTopicYN="Y">physiology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Predictive Value of Tests</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Pulmonary Diffusing Capacity</Descriptor>
<SubHeading MajorTopicYN="Y">physiology</SubHeading>
</MeshHeading>
<MeshHeading>
<Descriptor>Spirometry</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Support, Non-U.S. Gov't</Descriptor>
</MeshHeading>
<MeshHeading>
<Descriptor>Vital Capacity</Descriptor>
<SubHeading MajorTopicYN="Y">physiology</SubHeading>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation>
<MedlineID>99176754</MedlineID>
<PMID>10078868</PMID>
<DateCreated>
<Year>1999</Year>
<Month>06</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted>
<Year>1999</Year>
<Month>06</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0041-0101</ISSN>
<JournalIssue>
<Volume>37</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1999</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Bibliography of toxinology.</ArticleTitle>
<Pagination>
<MedlinePgn>399-404</MedlinePgn>
</Pagination>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Bibliography</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>ENGLAND</Country>
<MedlineTA>Toxicon</MedlineTA>
<MedlineCode>VWT</MedlineCode>
<NlmUniqueID>1307333</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<CASRegistryNumber>0</CASRegistryNumber>
<NameOfSubstance>Toxins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<Descriptor MajorTopicYN="Y">Toxins</Descriptor>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
</MedlineCitationSet>